Offc Action Outgoing

RHYTHM

Rhythm Pharmaceuticals, Inc.

U.S. Trademark Registration No. 88421834 - RHYTHM - 114020-0009

To: Rhythm Pharmaceuticals, Inc. (trademarks@morganlewis.com)
Subject: U.S. Trademark Registration No. 88421834 - RHYTHM - 114020-0009
Sent: 02/21/20 07:58:20 AM
Sent As: ecomitu@uspto.gov
Attachments:

United States Patent and Trademark Office (USPTO)

 

U.S. Application Serial No. 88421834

 

Mark:  RHYTHM

 

 

 

 

Correspondence Address: 

       DAVID O. JOHANSON, ESQ.

       MORGAN, LEWIS & BOCKIUS LLP

       ONE FEDERAL STREET

       ATTN: TMSU

       BOSTON, MA 02110

 

 

 

 

 

 

Applicant:  Rhythm Pharmaceuticals, Inc.

 

 

 

Reference/Docket No. 114020-0009        

 

Correspondence Email Address: 

       trademarks@morganlewis.com

 

 

 

NOTICE THAT PROCESSING OF

REQUEST TO DIVIDE APPLICATION IS COMPLETED

No Response Required

 

 

Issue date:  February 21, 2020

 

The request to divide application serial no. 88421834 filed on January 22, 2020 has been processed as follows:

 

(1)      Parent (original) application serial no. 88421834 contains the following goods in class(es): 

 

5 (Pharmaceuticals and medicines for the treatment of metabolic diseases and disorders, including obesity, diabetes, metabolic syndrome and cachexia, and gastrointestinal diseases and disorders, including gastroparesis, post-operative ileus, chronic constipation, and inflammatory bowel disease). 

 

To avoid abandonment, applicant must continue to file requests for extension of time to file a statement of use (extension requests) or a statement of use within the six-month period after the issuance of the notice of allowance or before expiration of a previously granted extension period.  37 C.F.R. §§2.88(a), 2.89(a)-(b).

 

(2)      Child application serial no. 88976878 contains the following services in class(es): 

 

42 (Research and product development services in the fields of metabolic diseases and disorders, including obesity, diabetes, metabolic syndrome and cachexia, and gastrointestinal diseases and disorders, including gastroparesis, post-operative ileus, chronic constipation, and inflammatory bowel disease). 

 

A statement of use filed on January 22, 2020 meets the minimum filing requirements and has been placed in the child application.  The statement of use will be routed to the examining attorney for examination and, if it does not meet all the statutory requirements, the examining attorney will notify the applicant.

 

37 C.F.R. §2.87; see TMEP §§1110 et seq. 

 

Direct questions about this notice to the assigned Intent-to-use staff member below.

 

 

/Tracy Welch/

Tracy Welch

Paralegal Specialist

OFC OF TM SVC

ITU/Divisional Unit

571-272-9631

tracy.welch@uspto.gov

 

 

 

U.S. Trademark Registration No. 88421834 - RHYTHM - 114020-0009

To: Rhythm Pharmaceuticals, Inc. (trademarks@morganlewis.com)
Subject: U.S. Trademark Registration No. 88421834 - RHYTHM - 114020-0009
Sent: 02/21/20 07:58:20 AM
Sent As: ecomitu@uspto.gov
Attachments:





United States Patent and Trademark Office (USPTO)


USPTO Official Notice


Office action (Official Letter) or Notice has issued
on 02/21/2020 for
U.S.Trademark Application Serial No. 88421834


Your trademark document has been reviewed by an Intent-to-use staff member. As part of that review, the assigned staff member has issued you an official letter or notice. If a response is required, you must respond by the specified deadline or your application will be abandoned. Please follow the steps below.

(1) Read the official letter or notice.

(2) Direct questions about the contents of the official letter or notice to the assigned staff member identified in the letter. Direct questions about navigating USPTO electronic forms, the USPTO website , the application process, the status of your application, and/or whether there are outstanding deadlines or documents related to your file to the Trademark Assistance Center (TAC).

(3) Response may be required. Carefully review the Office action to determine (1) if a response is required, (2) the applicable response time period, and (3) how to respond using the Trademark Electronic Application System (TEAS). The response must be received by the USPTO before midnight Eastern Time of the last day of the response period.



GENERAL GUIDANCE


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed